Skip to main content
38°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ardelyx, Inc. - Common Stock
(NQ:
ARDX
)
5.440
-0.180 (-3.20%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 12, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ardelyx, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
The Latest Analyst Ratings for Ardelyx
December 01, 2023
Via
Benzinga
Ardelyx, Inc. Reports Employment Inducement Grants
November 21, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
7 Penny Stocks You’ll Regret Not Buying Soon: November 2023
November 21, 2023
Unlock robust upside potential by wagering on these top penny stocks to buy in a volatile market at this time.
Via
InvestorPlace
Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
November 21, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Why Ardelyx Stock Soared Today
October 31, 2023
Ardelyx delivered a strong quarter thanks to solid demand for its first FDA-approved product. Here's what investors need to know.
Via
The Motley Fool
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
November 15, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Announces Departure of Board Member
November 13, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx to Participate at the Jefferies London Healthcare Conference
November 10, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
5 OTC Stocks With The Potential To Explode In 2024
November 08, 2023
Investors who are ready to dive into the OTC pool have more options than ever, both with the number of stocks to choose from and available investing platforms.
Via
Benzinga
Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States
November 06, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
November 03, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On Tuesday
October 31, 2023
U.S. stocks traded lower, with the Dow Jones falling more than 50 points on Tuesday. Here are some major stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance
October 31, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
October 30, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
3 Penny Stocks to Buy and Hold for the Next 10 Years
October 29, 2023
These three penny stocks are the ones to buy and hold through the market conditions and the years to come for returns.
Via
InvestorPlace
Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023
October 23, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tesla, Nokia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
October 19, 2023
U.S. stock futures traded lower this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Why Ardelyx Stock Popped Today
October 18, 2023
Ardelyx finally received the long-awaited FDA approval for its chronic kidney disease drug.
Via
The Motley Fool
Exposures
Product Safety
Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
October 18, 2023
Conference call scheduled for 8:00 a.m. Eastern Time
From
Ardelyx, Inc.
Via
GlobeNewswire
Crude Oil Rises Sharply; Ardelyx Shares Spike Higher
October 18, 2023
U.S. stocks traded lower toward the end of trading, with the S&P 500 falling more than 1% on Wednesday. The Dow traded down 0.70% to 33,760.26 while the NASDAQ fell 1.45% to 13,338.71. The S&P 500 also...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Why Nuvve Holding Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
October 18, 2023
Gainers Shift Technologies, Inc. (NASDAQ: SFT) shares climbed 107.8% to $0.2239. Shift Technologies recently said it will file for Chapter 11 bankruptcy protection.
Via
Benzinga
Topics
Bankruptcy
Exposures
Financial
Legal
Abbott Laboratories, Nasdaq, Spirit AeroSystems And Other Big Stocks Moving Higher On Wednesday
October 18, 2023
U.S. stocks traded lower, with the Dow Jones falling around 50 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Ardelyx Inc. (NASDAQ: ARDX) is One of Wednesday Morning’s Most Active Stocks
October 18, 2023
Via
Investor Brand Network
Workhorse (WKHS) Stock Jumps on Drone Business Success
October 18, 2023
Workhorse stock is getting a boost on Wednesday morning after providing WKHS investors with an update on its drone business.
Via
InvestorPlace
FDA Sends ARDX Stock Soaring After Approving Ardelyx’s Kidney Disease Drug
October 18, 2023
ARDX stock is rallying after the U.S. Food and Drug Administration (FDA) approved Ardelyx's kidney disease treatment.
Via
InvestorPlace
Exposures
Product Safety
After Initial Rejection, FDA Approves Ardelyx's Kidney Disease-Related Drug
October 18, 2023
The FDA approved Ardelyx Inc's (NASDAQ: ARDX) Xphozah (tenapanor), the first and only phosphate absorption inhibitor, indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on...
Via
Benzinga
Exposures
Product Safety
Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital
October 17, 2023
Additional non-dilutive capital extends runway to support the launch of XPHOZAH® (tenapanor) and continued commercial investment into IBSRELA® (tenapanor) in the U.S.
From
Ardelyx, Inc.
Via
GlobeNewswire
FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor
October 17, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
October 17, 2023
It's time for another dive into the biggest pre-market stock movers as we list out the top stocks worth watching on Tuesday!
Via
InvestorPlace
Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA
October 13, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.